685 A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model

• David Ciccone,
• Vad Lazari,
• Ian Linney,
• Michael Briggs,
• Samantha Carreiro,
• Joshua McElwee,
• Ian Waddell,
• Chris Hill,
• Christine Loh,
• Peter Tummino,
• Alan Collis,
• Neelu Kaila

Affiliations

David Ciccone

1Nimbus Therapeutics, Cambridge, MA, USA

Vad Lazari

2Charles River Laboratories, Chesterford Research Park, UK

Ian Linney

2Charles River Laboratories, Chesterford Research Park, UK

Michael Briggs

2Charles River Laboratories, Chesterford Research Park, UK

Samantha Carreiro

1Nimbus Therapeutics, Cambridge, MA, USA

Joshua McElwee

1Nimbus Therapeutics, Cambridge, MA, USA

Ian Waddell

2Charles River Laboratories, Chesterford Research Park, UK

Chris Hill

2Charles River Laboratories, Chesterford Research Park, UK

Christine Loh

1Nimbus Therapeutics, Cambridge, MA, USA

Peter Tummino

1Nimbus Therapeutics, Cambridge, MA, USA

Alan Collis

1Nimbus Therapeutics, Cambridge, MA, USA

Neelu Kaila

1Nimbus Therapeutics, Cambridge, MA, USA